Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer

Cancer immunotherapy was selected as the Breakthrough of the Year 2013 by the editors of Science, in part because of the successful treatment of refractory hematological malignancies with adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells. Effective treatment of B cell leukemia...

Descripción completa

Detalles Bibliográficos
Autores principales: Hillerdal, Victoria, Essand, Magnus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Leading Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544486/
https://www.ncbi.nlm.nih.gov/pubmed/25859858
http://dx.doi.org/10.1007/s40259-015-0122-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544486/
https://www.ncbi.nlm.nih.gov/pubmed/25859858
http://dx.doi.org/10.1007/s40259-015-0122-9

Ejemplares similares